Literature DB >> 15043204

HIV-1 coreceptor usage, transmission, and disease progression.

Sean M Philpott1.   

Abstract

HIV-1 coreceptor usage is believed to play a critical role in pathogenesis. To initiate infection, HIV-1 interacts with two cell surface receptors; CD4 is the primary receptor and the beta-chemokine receptors CCR5 and CXCR4 usually serve as secondary receptors. HIV-1 strains transmitted in vivo generally use CCR5. Viruses that use CCR5 (R5 viruses) appear to be associated with relatively stable infection. Years after chronic infection is established, CXCR4 utilizing strains emerge in approximately 50% of infected individuals. Viruses that use the coreceptor CXCR4 (X4 viruses) are associated with rapid CD4+ cell decline and disease progression. However, the mechanism by which X4 viruses are associated with accelerated disease progression has never been properly elucidated. For example, the association between X4 virus and acceleration of HIV-1 disease progression has been ascribed to the expanded spectrum of CXCR4+ precursor cells susceptible to infection by X4 strains. It has also been postulated that the decline of the host immune system associated with clinical AIDS may allow X4 viruses to evolve and replicate freely in late-stage infection. Discriminating between these and other alternatives is central to increasing our understanding of the fundamental pathogenic processes involved in HIV-1 infection. In this article, we critically review those studies published over the last few years that purport to examine the relationship between HIV-1 coreceptor usage, transmission, CD4+ T-cell depletion, and disease progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15043204     DOI: 10.2174/1570162033485357

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  42 in total

1.  Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope.

Authors:  Eric G Meissner; Karen M Duus; Feng Gao; Xiao-Fang Yu; Lishan Su
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

2.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

3.  Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects.

Authors:  Kimberly K Adkison; Anne Shachoy-Clark; Lei Fang; Yu Lou; Kathy O'Mara; M Michelle Berrey; Stephen C Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  HIV and CXCR4 in a kiss of autophagic death.

Authors:  Beth Levine; Donald L Sodora
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

Review 5.  Cross-species virus transmission and the emergence of new epidemic diseases.

Authors:  Colin R Parrish; Edward C Holmes; David M Morens; Eun-Chung Park; Donald S Burke; Charles H Calisher; Catherine A Laughlin; Linda J Saif; Peter Daszak
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

6.  Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.

Authors:  Signe Fransen; Gary Bridger; Jeannette M Whitcomb; Jonathan Toma; Eric Stawiski; Neil Parkin; Christos J Petropoulos; Wei Huang
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

7.  Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.

Authors:  Lachlan Gray; Melissa J Churchill; Niamh Keane; Jasminka Sterjovski; Anne M Ellett; Damian F J Purcell; Pantelis Poumbourios; Chenda Kol; Bin Wang; Nitin K Saksena; Steven L Wesselingh; Patricia Price; Martyn French; Dana Gabuzda; Paul R Gorry
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

8.  Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody.

Authors:  Brian J Willett; Martin Kraase; Nicola Logan; Elizabeth L McMonagle; Ayman Samman; Margaret J Hosie
Journal:  Retrovirology       Date:  2010-04-26       Impact factor: 4.602

9.  CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells.

Authors:  Grant R Campbell; Stephen A Spector
Journal:  J Biol Chem       Date:  2008-09-10       Impact factor: 5.157

10.  Vpu serine 52 dependent counteraction of tetherin is required for HIV-1 replication in macrophages, but not in ex vivo human lymphoid tissue.

Authors:  Michael Schindler; Devi Rajan; Carina Banning; Peter Wimmer; Herwig Koppensteiner; Alicja Iwanski; Anke Specht; Daniel Sauter; Thomas Dobner; Frank Kirchhoff
Journal:  Retrovirology       Date:  2010-01-15       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.